Search
Tools content (print, share, increase/decrease text size):
-
Size
Middle area:Press releases 2010Press releases are intended to journalists, analysts and investors. Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology in Diabetes and Related DisordersDecember 21, 2010 Sanofi-aventis and Avila Therapeutics Sign Global Alliance to Develop Targeted Covalent Oncology DrugsDecember 20, 2010 Sanofi-aventis and Merck KGaA Sign Agreement to Jointly Investigate Novel Combinations Against CancerDecember 17, 2010 Composition of the Board of Directors of sanofi-aventisDecember 15, 2010 Sanofi-aventis appoints Dr. Elias Zerhouni, President, Global Research & DevelopmentDecember 14, 2010 Sanofi-aventis Extends Tender Offer for all Outstanding Shares of GenzymeDecember 13, 2010 Sanofi-aventis announces Wayne Pisano’s retirement and appoints Olivier Charmeil Senior Vice President VaccinesDecember 10, 2010 Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board ActionsNovember 08, 2010 Sanofi Pasteur’s Dengue Vaccine in Final Stage of Clinical DevelopmentNovember 04, 2010 Sanofi-aventis to Acquire BMP Sunstone creating a Strong Consumer Healthcare Platform in ChinaOctober 28, 2010 Resilient sales and business EPS in Q3 2010October 28, 2010 Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple SclerosisOctober 26, 2010 Sanofi-aventis Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of GenzymeOctober 20, 2010 Sanofi-aventis Establishes Research Collaboration with Harvard UniversityOctober 18, 2010 Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis PatientsOctober 15, 2010 Final Results from Phase II Study Confirm BSI-201 (Iniparib) Prolongs Survival in Metastatic Triple Negative Breast CancerOctober 10, 2010 Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in CashOctober 04, 2010 Jevtana® Improves Survival in Advanced Prostate Cancer PatientsOctober 01, 2010 Once-Daily Lixisenatide in Combination with Basal Insulin Demonstrates Significant Improvement in Glucose ControlSeptember 30, 2010 Sanofi Pasteur to Acquire VaxDesign, a U.S. biotechnology companySeptember 27, 2010 Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in OncologySeptember 23, 2010 Clinical Update on TAMARIS Phase III Trial for NV1FGFSeptember 22, 2010 Sanofi-aventis presents its innovative blood glucose monitoring devices to enhance self-management of diabetesSeptember 21, 2010 Adding Lantus® to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients with Type 2 DiabetesSeptember 20, 2010 Investigational Compound Once-Daily Lixisenatide Demonstrated Significant Improvement in Glucose Control in Patients with Type 2 DiabetesSeptember 20, 2010 Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring CommitteeSeptember 08, 2010 Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular HospitalizationSeptember 01, 2010 Teriflunomide Significantly Reduced Annualized Relapse Rate and was well Tolerated in MS patientsAugust 30, 2010 Sanofi-aventis Announces Non-Binding Offer to Acquire GenzymeAugust 29, 2010 Multaq® First-line Option in New 2010 ESC Guidelines for the Management of Atrial FibrillationAugust 29, 2010 Sanofi-aventis Comments on Injunctive Relief Hearing Regarding Lovenox®August 26, 2010 Availability on line of the Group’s half-year financial report for 2010July 30, 2010 Sanofi-aventis and Merck appoint Raul Kohan as CEO for the new Animal Health joint ventureJuly 27, 2010 Sanofi-aventis expresses concern over the approval of another version of enoxaparin sodium in the U.S.July 23, 2010 Sanofi Pasteur Inaugurates its Hi-Tech Influenza Vaccine Facility in Shenzhen, ChinaJuly 23, 2010 Jevtana® (cabazitaxel) Injection Now Available in the U.S.July 19, 2010 Sanofi-aventis and JDRF Form Partnership to Improve Therapies, Work Toward Cure for Type 1 DiabetesJuly 01, 2010 Rifapentine is granted Orphan Drug Status by European Commission for Treatment of TuberculosisJuly 01, 2010 Sanofi-aventis to acquire TargeGen Inc., a US biopharmaceutical companyJune 30, 2010 Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog InsulinJune 26, 2010 Improved Outcomes for Patients Treated with Lantus® and Apidra® Regimen Compared with Sliding Scale InsulinJune 25, 2010 Sanofi-aventis and Metabolex enter into an Exclusive Worldwide Licensing Agreement for a Novel Oral Antidiabetic to treat Type II DiabetesJune 25, 2010 Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA TherapeuticsJune 22, 2010 Jevtana® (cabazitaxel) Injection Approved by U.S. FDA After Priority ReviewJune 17, 2010 Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious DiseasesJune 08, 2010 Teriflunomide in adjunct to interferon beta significantly improved outcomes of Multiple Sclerosis patientsJune 05, 2010 Sanofi-aventis and US Biopharmaceutical Company Ascenta Therapeutics Sign License Agreement in OncologyJune 04, 2010 The Charité University in Berlin and sanofi-aventis Sign an Innovative Research Cooperation AgreementMay 31, 2010 Sanofi-aventis and Generics Leader Nichi-Iko to Establish New Joint Venture for Generics in JapanMay 28, 2010 Updated Phase 3 Survival Results with Cabazitaxel in Patients with Advanced Hormone-Refractory Prostate Cancer, Presented at ASCOMay 27, 2010 Sanofi-aventis Establishes Strategic Alliance with MIT’s Center for Biomedical InnovationMay 26, 2010 Sanofi-aventis Wins the 2010 Global Business Coalition Core Competence Award for its Innovative Malaria Access to Medicines ProgramMay 25, 2010 Sanofi-aventis to reinforce its Consumer Health Care platform in PolandMay 19, 2010 Combined General Shareholder Meeting of May 17, 2010May 17, 2010 Sanofi-aventis announces the creation of the “Sanofi Espoir” Corporate FoundationMay 17, 2010 Sanofi-aventis initiates 10,000 patient study with Multaq® in permanent atrial fibrillationMay 12, 2010 Sanofi-aventis and Glenmark Pharmaceuticals Sign License Agreement on Novel Agents to treat Chronic PainMay 03, 2010 Change in sanofi-aventis Executive CommitteeApril 30, 2010 Sanofi-aventis Announces Court Decision Resolving Eloxatin® U.S. Patent LitigationApril 23, 2010 Sanofi-aventis’ Combined General Shareholder Meeting to be held May 17, 2010April 20, 2010 Once Daily Lixisenatide (AVE 0010) Given as Monotherapy Successfully Meets Phase III Study Endpoints in DiabetesApril 15, 2010 Sanofi Pasteur Partners with U.S. Naval Medical Research Center to Advance Development of Travelers’ Diarrhea VaccineApril 12, 2010 Sanofi-aventis successfully completes a tap on its October 2014 bond for 500 million EurosApril 08, 2010 Sanofi-aventis and CureDM Sign Exclusive Worldwide License Agreement on Novel Regenerative Compound to Treat DiabetesApril 08, 2010 Sanofi-aventis makes updated settlement announcement regarding Eloxatin® U.S. Patent litigationApril 06, 2010 Sanofi-aventis amends its Alliance Agreement with Warner Chilcott regarding Actonel® (risedronate sodium) in the United States and Puerto RicoApril 05, 2010 Sanofi-aventis announces settlement of Eloxatin® U.S. patent litigationApril 01, 2010 Sanofi-aventis invests €150 million in France and continues its Change towards BiotechnologiesMarch 31, 2010 Sanofi-aventis & AgaMatrix enter into worldwide agreement on blood glucose monitoring (BGM) solutionsMarch 31, 2010 Multaq® receives positive recommendation by NICE in new appraisal consultation documentMarch 30, 2010 Sanofi-aventis confirms Quality and Supply of Plavix®, Iscover® and Clopidogrel Winthrop®March 26, 2010 DuoPlavin®/DuoCover® Dual antiplatelet combination tablet newly approved in the European UnionMarch 24, 2010 Filing of the 2009 U.S. Form 20-F and French “Document de Référence” and Annual Financial ReportMarch 12, 2010 Sanofi-aventis Successfully Completes the Acquisition of Chattem, Inc.March 11, 2010 Sanofi-aventis and Merck to create a Global Leader in Animal HealthMarch 09, 2010 Cabazitaxel increased survival for patients with advanced hormone-refractory prostate cancerMarch 04, 2010 Sanofi Pasteur’s A(H1N1) vaccine HUMENZA® recommended by European Medicines AgencyFebruary 19, 2010 Sanofi-aventis strengthens commitment to Research in France through partnership with AVIESANFebruary 17, 2010 “My child matters” supports seven new childhood cancer care projectsFebruary 15, 2010 Sanofi-aventis delivers double-digit EPS¹ growth in 2009 as the Transformation program progressesFebruary 10, 2010 Sanofi-aventis successfully completes tender offer for Chattem, Inc.February 09, 2010 Sanofi-aventis Signs Agreements to Establish New Consumer Healthcare Joint Venture in China with Minsheng Pharmaceutical GroupJanuary 29, 2010 Sanofi-aventis Obtains Antitrust Clearance in Connection With Chattem, Inc. Tender OfferJanuary 26, 2010 Sanofi-aventis and employees unite for the victims of HaitiJanuary 21, 2010 Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa InfectionsJanuary 11, 2010 Sanofi-aventis Commences Tender Offer for all Outstanding Shares of Chattem, Inc.January 11, 2010 Sanofi-aventis reinforces its Consumer Health Care ManagementJanuary 08, 2010 |
Tools menu:
© Sanofi 2004-2013 - All rights reserved - Update: January 28, 2013
